Literature DB >> 33531693

Single-dose intraoperative radiotherapy during lumpectomy for breast cancer: an innovative patient-centred treatment.

Jayant S Vaidya1, Max Bulsara2,3, Michael Baum2, Jeffrey S Tobias4.   

Abstract

In the randomised TARGIT-A trial, risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy was non-inferior to whole-breast external beam radiotherapy, for local recurrence. In the long-term, no difference was found in any breast cancer outcome, whereas there were fewer deaths from non-breast-cancer causes. TARGIT-IORT should be included in pre-operative consultations with eligible patients.

Entities:  

Mesh：

Year:  2021        PMID： 33531693      PMCID： PMC7851812          DOI： 10.1038/s41416-020-01233-5

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  32 in total

1.  Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Authors:  Ian H Kunkler; Linda J Williams; Wilma J L Jack; David A Cameron; J Michael Dixon
Journal:  Lancet Oncol       Date:  2015-01-28       Impact factor: 41.316

2.  Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial.

Authors:  R W Blamey; T Bates; U Chetty; S W Duffy; I O Ellis; D George; E Mallon; M J Mitchell; I Monypenny; D A L Morgan; R D Macmillan; J Patnick; S E Pinder
Journal:  Eur J Cancer       Date:  2013-03-21       Impact factor: 9.162

3.  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Authors:  Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl McCormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman B Muss; Eric Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton
Journal:  N Engl J Med       Date:  2004-09-02       Impact factor: 91.245

4.  An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).

Authors:  Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Christobel Saunders; Chris Brew-Graves; Ingrid Potyka; Stephen Morris; Hrisheekesh J Vaidya; Norman R Williams; Michael Baum
Journal:  Health Technol Assess       Date:  2016-09       Impact factor: 4.014

5.  Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

Authors:  Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood
Journal:  J Clin Oncol       Date:  2013-05-20       Impact factor: 44.544

6.  Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial.

Authors:  Umberto Veronesi; Roberto Orecchia; Patrick Maisonneuve; Giuseppe Viale; Nicole Rotmensz; Claudia Sangalli; Alberto Luini; Paolo Veronesi; Viviana Galimberti; Stefano Zurrida; Maria Cristina Leonardi; Roberta Lazzari; Federica Cattani; Oreste Gentilini; Mattia Intra; Pietro Caldarella; Bettina Ballardini
Journal:  Lancet Oncol       Date:  2013-11-11       Impact factor: 41.316

7.  Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial.

Authors:  Icro Meattini; Livia Marrazzo; Calogero Saieva; Isacco Desideri; Vieri Scotti; Gabriele Simontacchi; Pierluigi Bonomo; Daniela Greto; Monica Mangoni; Silvia Scoccianti; Sara Lucidi; Lisa Paoletti; Massimiliano Fambrini; Marco Bernini; Luis Sanchez; Lorenzo Orzalesi; Jacopo Nori; Simonetta Bianchi; Stefania Pallotta; Lorenzo Livi
Journal:  J Clin Oncol       Date:  2020-08-24       Impact factor: 44.544

8.  Multicentricity of breast cancer: whole-organ analysis and clinical implications.

Authors:  J S Vaidya; J J Vyas; R F Chinoy; N Merchant; O P Sharma; I Mittra
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

9.  Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.

Authors:  Jayant S Vaidya; Max Bulsara; Christobel Saunders; Henrik Flyger; Jeffrey S Tobias; Tammy Corica; Samuele Massarut; Frederik Wenz; Steffi Pigorsch; Michael Alvarado; Michael Douek; Wolfgang Eiermann; Chris Brew-Graves; Norman Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McCready; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; Michael Baum; David Joseph
Journal:  JAMA Oncol       Date:  2020-07-09       Impact factor: 31.777

10.  Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.

Authors:  Jayant S Vaidya; Max Bulsara; Michael Baum; Frederik Wenz; Samuele Massarut; Steffi Pigorsch; Michael Alvarado; Michael Douek; Christobel Saunders; Henrik L Flyger; Wolfgang Eiermann; Chris Brew-Graves; Norman R Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Tammy Corica; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McCready; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; David J Joseph; Jeffrey S Tobias
Journal:  BMJ       Date:  2020-08-19
View more
  4 in total

Review 1.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

2.  Endocrine therapy with accelerated Partial breast irradiatiOn or exclusive ultra-accelerated Partial breast irradiation for women aged ≥ 60 years with Early-stage breast cancer (EPOPE): The rationale for a GEC-ESTRO randomized phase III-controlled trial.

Authors:  Jean-Michel Hannoun-Levi; Emmanuel Chamorey; Rabia Boulahssass; Csaba Polgar; Vratislav Strnad
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-22

3.  Global adoption of single-shot targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer-better for patients, better for healthcare systems.

Authors:  Jayant Sharad Vaidya; Uma Jayant Vaidya; Michael Baum; Max Kishor Bulsara; David Joseph; Jeffrey S Tobias
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

4.  New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer.

Authors:  Jayant S Vaidya; Max Bulsara; Michael Baum; Frederik Wenz; Samuele Massarut; Steffi Pigorsch; Michael Alvarado; Michael Douek; Christobel Saunders; Henrik Flyger; Wolfgang Eiermann; Chris Brew-Graves; Norman R Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Tammy Corica; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McReady; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; David Joseph; Jeffrey S Tobias
Journal:  Br J Cancer       Date:  2021-05-25       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.